VIGONVITA-B (02630): Shareholders voluntarily extend lock-up period

VIGONVITA-B (02630) announced that recently, the Company received notices from all pre-IPO investors, including the controlling shareholder, pursuant to which, based on their high recognition of the value of the Company's R&D pipeline, the commercialization prospects of approved drugs, and the core management team, they have each undertaken that during the extended lock-up period of 7 months or 4 months following the expiry date of the original lock-up period (the "Extended Lock-up Period"), they will not reduce their respective shareholdings in the Company in any manner. The Company believes that the Extended Lock-up Period demonstrates the aforementioned shareholders' full confidence in the Company's future prospects and long-term value.